Cinzia Vetrei

Naples, Italy

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

CXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cells.

CXCR4, CXCR7 and PBRM1 are responsible for everolimus and cabozantinib resistance in human renal cancer cells.

Journal: Cell death discovery
Published: July 30, 2025

Comprehensive structural investigation of a potent and selective CXCR4 antagonist via crosslink modification.

Comprehensive structural investigation of a potent and selective CXCR4 antagonist via crosslink modification.

Journal: European journal of medicinal chemistry
Published: July 21, 2024

Disulfide bond replacement with non-reducible side chain to tail macrolactamization for the development of potent and selective CXCR4 peptide antagonists endowed with flanking binding sites.

Disulfide bond replacement with non-reducible side chain to tail macrolactamization for the development of potent and selective CXCR4 peptide antagonists endowed with flanking binding sites.

Journal: European journal of medicinal chemistry
Published: May 20, 2024

Novel Combinations of Human Immunomodulatory mAbs Lacking Cardiotoxic Effects for Therapy of TNBC.

Novel Combinations of Human Immunomodulatory mAbs Lacking Cardiotoxic Effects for Therapy of TNBC.

Journal: Cancers
Published: December 06, 2021

Interactions of Spike-RBD of SARS-CoV-2 and Platelet Factor 4: New Insights in the Etiopathogenesis of Thrombosis.

Interactions of Spike-RBD of SARS-CoV-2 and Platelet Factor 4: New Insights in the Etiopathogenesis of Thrombosis.

Journal: International journal of molecular sciences
Published: July 20, 2021

Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments.

Immunomodulatory mAbs as Tools to Investigate on Cis-Interaction of PD-1/PD-L1 on Tumor Cells and to Set Up Methods for Early Screening of Safe and Potent Combinatorial Treatments.

Journal: Cancers
Published: April 26, 2021

Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2.

Novel human neutralizing mAbs specific for Spike-RBD of SARS-CoV-2.

Journal: Scientific reports
Published: March 22, 2021

Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells.

Isolation of Two Novel Human Anti-CTLA-4 mAbs with Intriguing Biological Properties on Tumor and NK Cells.

Journal: Cancers
Published: July 07, 2020

Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells.

Ipilimumab and Its Derived EGFR Aptamer-Based Conjugate Induce Efficient NK Cell Activation against Cancer Cells.

Journal: Cancers
Published: December 19, 2019

Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling.

Novel Human Anti-PD-L1 mAbs Inhibit Immune-Independent Tumor Cell Growth and PD-L1 Associated Intracellular Signalling.

Journal: Scientific reports
Published: July 05, 2019

Novel Human Bispecific Aptamer-Antibody Conjugates for Efficient Cancer Cell Killing.

Novel Human Bispecific Aptamer-Antibody Conjugates for Efficient Cancer Cell Killing.

Journal: Cancers
Published: June 26, 2019

Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations.

Wee1 Rather Than Plk1 Is Inhibited by AZD1775 at Therapeutically Relevant Concentrations.

Journal: Cancers
Published: April 24, 2019
Showing 1-12 of 13

Last Updated: 09/26/2026